National, Observational, Multicentric Retrospective Study to Understand Treatment Patterns, Patient Journey and Characteristics with Stage III Non-Small Cell Lung Cancer Patients in Turkey: Stone Trial

Abstract

6 (21%), 6 (21%), and 5 (17%) patients, respectively. Acute Grade 3 toxicities were fatigue (n Z 1, 3%) and dyspnea (n Z 1, 3%). Conclusion: In this first clinical report of TRT for LC on a 6X FFF ORL, daily CBCT-guided treatment was fast (avg. 9 min in room) and RT was delivered safely with respect to dosimetry, acute toxicity, and disease control. Thus, use of a 6X FFF ORL for TRT may increase LC patient throughput, without a detriment in RT quality. This has significant implications for patients receiving time-intensive combined modality therapy, and globally in more resource-restricted countries.